Phase I trial of ilmofosine as a 24 hour infusion weekly
β Scribed by M. Mehren; B. J. Giantonio; C. McAleer; R. Schilder; J. McPhillips; P. J. O'Dwyer
- Publisher
- Springer US
- Year
- 1995
- Tongue
- English
- Weight
- 491 KB
- Volume
- 13
- Category
- Article
- ISSN
- 0167-6997
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## BACKGROUND. Reports of in vitro experiments in colorectal carcinoma cells suggest that prolonged cellular exposure to 5-fluorouracil (5-FU) combined with relatively low concentrations of leucovorin (LV) provides optimal enhancement of 5-FU efficacy. In this study, a simplified regimen of weekly
ICRF-187 was given to 62 evaluable patients with advanced solid tumors in a Phase I clinical trial. Weekly infusions were given in dosages ranging from 0.85 g/m2 to 7.42 g/m2 for a total of four weeks with a two week rest period between courses. Dose-limiting hematological toxicity was seen in heavi